Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
Please join us for an interactive session taking place Monday, April 17th, at the AACR Annual Meeting 2023. The Meet the Research Grant Reviewers session, will give you an opportunity to ask AACR grant reviewers, Dr. DeGregori and Dr. Iacobuzio-Donahue, any questions you may have. We offer you a sneak peak of what you can learn from attending the session here!
Between April 14 – 19, the 2023 AACR Annual Meeting will welcome the best cancer scientists from all over the world to the Orange County Convention Center, Orlando, Florida. We are excited to announce the AACR grantees selected to present their work in oral and poster presentations. We are extremely proud and excited to hear of the progress they have made with support from the AACR and its funding partners!
Metastatic prostate cancer (PCa) remains a leading cause of death in men worldwide (1). Although effective treatments exist, therapy resistance in PCa is common. Dr. Rodriguez-Bravo and her research team recently uncovered high chromosomal instability (CIN) and increased mitotic...
Head and neck cancer (HNC), describing cancers of the oral cavity, throat, nose, and sinuses, is the sixth most common cancer worldwide accounting for 300,000 cancer deaths each year. Epidemiological data has shown disparities between HNC screening, detection, treatment,...
Dedicated to accelerating the conquest of cancer, the AACR is a unique organization committed to funding research projects across all cancer sites and researchers at all career levels. In partnership with the Pancreatic Cancer Action Network (PanCAN), a nationwide organization dedicated to pancreatic cancer, the AACR-PanCAN Pathway to Leadership Grant was established in 2010. Running until 2017, the joint program offered $600,000 over five years to facilitate the career transition of pancreatic cancer researchers from postdoctoral/clinical research fellow to independent faculty.
Treatment options for brain cancers, including aggressive glioblastoma, are limited despite the availability of several chemotherapeutic drugs due to the inability of these drugs to cross the blood-brain barrier (BBB). AACR-Novocure grantee Dr. Carsten Hagemann and his team showed that the use of low-intensity alternating electric fields known as Tumor Treating Fields (TTFields), an FDA-approved treatment modality, can facilitate drugs crossing the BBB. Using multiple models, they elucidated the mechanisms driving this action.
We are extremely proud of our past and present grantees who published their findings this past year on their work that has been made possible through the support of the AACR and its funding partners.
Recipient of a 2021 AACR Career Development Award to Further Diversity, Equity, and Inclusion in Pancreatic Cancer Research, Luisa Escobar-Hoyos, PhD, shares how the AACR grant has been a critical step in her quest for federal funding for her more unconventional approach to treat pancreatic cancer.
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children and young adults. Dr. Amit Sabnis, recipient of the 2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research, and his research team demonstrated the therapeutic potential of bi-steric mTORC1 inhibitors in FOXO1 fusion positive RMS.
Tuomas Tammela, MD, PhD shared how his 2018 AACR NextGen Grant led to the discovery of a new particularly malignant cell state in lung cancer. He lauds the benefits of grants such as the AACR Next Gen grants that provide robust support for research on fundamental biology.